Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients.

Suardi N, Gallina A, Capitanio U, Salonia A, Lughezzani G, Freschi M, Mottrie A, Rigatti P, Montorsi F, Briganti A.

Cancer. 2012 Feb 15;118(4):973-80. doi: 10.1002/cncr.26234. Epub 2011 Jul 12. Erratum in: Cancer. 2012 May 1;118(9):2560.

2.

Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer.

Suardi N, Briganti A, Gallina A, Salonia A, Karakiewicz PI, Capitanio U, Freschi M, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2010 Jun;105(11):1548-52. doi: 10.1111/j.1464-410X.2009.09057.x. Epub 2009 Nov 13.

3.

Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?

Ploussard G, Salomon L, Xylinas E, Allory Y, Vordos D, Hoznek A, Abbou CC, de la Taille A.

J Urol. 2010 Feb;183(2):539-44. doi: 10.1016/j.juro.2009.10.009. Epub 2009 Dec 14.

4.

Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features.

Suardi N, Capitanio U, Chun FK, Graefen M, Perrotte P, Schlomm T, Haese A, Huland H, Erbersdobler A, Montorsi F, Karakiewicz PI.

Cancer. 2008 Oct 15;113(8):2068-72. doi: 10.1002/cncr.23827.

5.

Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.

Steuber T, Budäus L, Walz J, Zorn KC, Schlomm T, Chun F, Ahyai S, Fisch M, Sauter G, Huland H, Graefen M, Haese A.

BJU Int. 2011 Jun;107(11):1755-61. doi: 10.1111/j.1464-410X.2010.09730.x. Epub 2010 Oct 13.

6.

Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy.

Salonia A, Gallina A, Briganti A, Zanni G, Suardi N, Capitanio U, Colombo R, Bertini R, Freschi M, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2011 Apr;107(8):1243-9. doi: 10.1111/j.1464-410X.2010.09582.x. Epub 2010 Sep 30.

8.

The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy.

Abdollah F, Scattoni V, Raber M, Roscigno M, Briganti A, Suardi N, Gallina A, Capitanio U, Freschi M, Salonia A, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2011 Aug;108(3):366-71. doi: 10.1111/j.1464-410X.2010.09876.x. Epub 2010 Nov 19.

9.

Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer.

Briganti A, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, Marchioro G, Kneitz B, Walz J, Frohneberg D, Bangma CH, Graefen M, Tizzani A, Frea B, Karnes RJ, Montorsi F, Van Poppel H, Spahn M.

Eur Urol. 2012 Mar;61(3):584-92. doi: 10.1016/j.eururo.2011.11.043. Epub 2011 Dec 2.

PMID:
22153925
10.

Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy.

Chun FK, Suardi N, Capitanio U, Jeldres C, Ahyai S, Graefen M, Haese A, Steuber T, Erbersdobler A, Montorsi F, Huland H, Karakiewicz PI.

Eur Urol. 2009 Mar;55(3):617-28-6. doi: 10.1016/j.eururo.2008.04.099. Epub 2008 May 15.

PMID:
18499335
11.

Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.

Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.

Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):714-24.

PMID:
15708249
12.

Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.

Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti JC Jr, Dorey F, Terris MK; SEARCH Database Study Group.

Urology. 2003 Apr;61(4):742-7.

PMID:
12670558
13.

Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.

Seiler D, Randazzo M, Klotz L, Grobholz R, Baumgartner M, Isbarn H, Recker F, Kwiatkowski M.

BJU Int. 2012 Jul;110(2):195-200. doi: 10.1111/j.1464-410X.2011.10707.x. Epub 2011 Nov 17.

15.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
16.

Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification.

Ploussard G, Masson-Lecomte A, Beauval JB, Ouzzane A, Bonniol R, Buge F, Fadli S, Rouprêt M, Rebillard X, Gaschignard N, Pfister C, Villers A, Soulié M, Salomon L; Prostate Cancer Committee of the French Association of Urology.

Urology. 2011 Sep;78(3):607-13. doi: 10.1016/j.urology.2011.05.021. Epub 2011 Jul 23.

PMID:
21783233
17.

Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy.

Thomas C, Pfirrmann K, Pieles F, Bogumil A, Gillitzer R, Wiesner C, Thüroff JW, Melchior SW.

BJU Int. 2012 Jan;109(2):214-9. doi: 10.1111/j.1464-410X.2011.10187.x. Epub 2011 May 18.

18.

Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.

Walz J, Chun FK, Klein EA, Reuther A, Graefen M, Huland H, Karakiewicz PI.

Eur Urol. 2009 Feb;55(2):412-19. doi: 10.1016/j.eururo.2008.11.005. Epub 2008 Nov 21.

PMID:
19027223
19.

Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Freedland SJ, Amling CL, Dorey F, Kane CJ, Presti JC Jr, Terris MK, Aronson WJ; Shared Equal Access Regional Cancer Hospital Database Study Group.

Urology. 2002 Oct;60(4):670-4.

PMID:
12385931
20.

Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer.

Palisaar RJ, Graefen M, Karakiewicz PI, Hammerer PG, Huland E, Haese A, Fernandez S, Erbersdobler A, Henke RP, Huland H.

Eur Urol. 2002 Feb;41(2):155-61.

PMID:
12074402

Supplemental Content

Support Center